News
A&G Pharmaceutical, Inc (A&G), with its Custom Antibody Division Precision Antibody has developed antibodies against COVID-19 antigens; Spike protein S1 and nucleocapsid protein (N-protein).
Our Anti-S1 protein mAbs:
- Available antibodies that are specific to RBD region and antibodies that recognize the S1 protein outside of the RBD region.
- COVID-19-specific (SARS-Cov2) and do not cross-react to SARS Cov1 (SARS Cov 2003) and MERS.
- Recognize the trimeric form of Cov-2 S1 protein similarly or better than the S1 monomer.
- Our anti-S1 and anti-RBD antibodies bind with high affinity to non-overlapping epitopes*, making them compatible with sandwich ELISA or lateral flow applications.
- Several selected antibodies can be used on Protein Simple Wes, on Western blot and for immunoprecipitation.
Our Anti-N protein mAbs:
We have developed > 100 distinct mAbs against nucleocapsid protein. We have selected antibodies that have many interesting properties for future diagnostic development:
- All selected antibodies bind equally well in the presence of 1% Triton X100
- Our anti-N protein antibodies bind with high affinity to non-overlapping epitopes*, making them compatible with sandwich ELISA or lateral flow applications.
- Selected antibodies can be used on Protein Simple Wes, on Western blot and for immunoprecipitation.
For more information please visit our website at www.precisionantibody.com
Or visit our virtual booth at PEGS Boston 2020, August 31-September 4, 2020.